NovoLog® is the #1 selling rapid-acting insulin, and puts improved control in patient hands with a FullSTEP®, manageable, patient-titrated approach.1,2,3

Benefits include:

  • Proven effective to lower A1C with multiple dosing approaches, including FullSTEP®, a patient-led titration study.3,4 Learn more

    Learn more
  • Clinically proven to help patients reach their goal with low rates of hypoglycemia.4 Learn more

    Learn more
  • Covered for more than 85% of managed carea patients nationwide.b Learn more

    Learn more

Delivery devices designed to meet patients’ needs

For use with NovoLog® FlexPen®, the #1 selling disposable, prefilled insulin device in the world.2 And introducing NovoPen Echo®, the first and only reusable insulin pen with a memory function and half-unit dosing.

Learn More

NovoLog® is proven effective across a broad range of patients

NovoLog® (insulin aspart [rDNA origin] injection) is approved for pump use in children and adults.

Services for professionals

With a NovoMedLink ID you can order product samples, check formulary status and more.

aManaged care plans only. Does not include Medicaid and Medicaid Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status is subject to change.

bFormulary data are provided by Fingertip Formulary® and are current as of [February 2013]. Because formularies do change and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage for individual patients. © 2013 Fingertip Formulary. All rights reserved.